Nelesh Govender
@neleshg.bsky.social
I study fungal and bacterial diseases. Prof at Wits. @nihr Global Health Research Prof. Hon Prof at MRC-CMM @uniofexeter, City-St George's and UCT. On sabbatical from NICD. MD, micro, epi 🌈
Reposted by Nelesh Govender
We brought together teams from 13 neonatal sepsis surveillance studies, conducted across 35 sites in South Asia and Africa, to pool data and estimate prevalence of capsule and O types amongst #Klebsiella pneumoniae causing sepsis in newborns, using Bayesian modelling.
July 1, 2025 at 9:47 AM
We brought together teams from 13 neonatal sepsis surveillance studies, conducted across 35 sites in South Asia and Africa, to pool data and estimate prevalence of capsule and O types amongst #Klebsiella pneumoniae causing sepsis in newborns, using Bayesian modelling.
Reposted by Nelesh Govender
Thanks for sharing.
There was also a recent State of the Art review in CID on the topic academic.oup.com/cid/article/...
There was also a recent State of the Art review in CID on the topic academic.oup.com/cid/article/...
State-of-the-Art Review: Use of Antimicrobials at the End of Life
Abstract. Navigating antibiotics at the end of life is a challenge for infectious disease (ID) physicians who remain deeply committed to providing patient-
academic.oup.com
May 8, 2025 at 3:24 PM
Thanks for sharing.
There was also a recent State of the Art review in CID on the topic academic.oup.com/cid/article/...
There was also a recent State of the Art review in CID on the topic academic.oup.com/cid/article/...
This recent article has really resonated with me - www.thelancet.com/journals/lan...
Antimicrobials in serious illness and end-of-life care: lifting the veil of silence
Global rates of antimicrobial consumption increased by 65% between 2000 and 2015,
by 16% between 2016 and 2023, and are estimated to increase by an additional 52% by
2030. Antimicrobial use and misuse...
www.thelancet.com
May 8, 2025 at 1:51 PM
This recent article has really resonated with me - www.thelancet.com/journals/lan...
Her clinical team was reluctant to talk to us about the futility of curative treatment or end-of-life care. They wanted to continue as though she would walk out of hospital.
This didn't make sense. We wanted her to be comfortable, and not to end her life in a busy noisy bright surgical ICU.
This didn't make sense. We wanted her to be comfortable, and not to end her life in a busy noisy bright surgical ICU.
May 8, 2025 at 1:51 PM
Her clinical team was reluctant to talk to us about the futility of curative treatment or end-of-life care. They wanted to continue as though she would walk out of hospital.
This didn't make sense. We wanted her to be comfortable, and not to end her life in a busy noisy bright surgical ICU.
This didn't make sense. We wanted her to be comfortable, and not to end her life in a busy noisy bright surgical ICU.